News about Biotechnology, Pharmaceutical and Healthcare

15:52 EST 21st December 2014 | BioPortfolio

Latest news articles in the life-science, healthcare, medical device, biotechnology and pharmaceuticals sectors. 

Showing News Articles 1–25 of 10,000+

Friday 19th December 2014

December 2014 Focus Newsletter

Chiesi gets first-ever European stem cell nod

Chiesi has received the first approval for an advanced therapy medicinal product containing stem cells for use in Europe. The regulator described the Italian company’s treatment as an innovative therapy that will be a ‘major step forward’ for patients. Holoclar is a treatment for moderate to severe forms of limbal stem cell deficiency (LSCD), a rare eye condition caused by physical or chemic...

FX06: Die verschlungene Entwicklung eines möglichen Ebola-Medikaments

Peptid zum Abdichten von “leck” gewordenen Blutgefäßen -Entdeckt, erprobt, dann im Dschungel der Finanzierungserfordernisse zunächst “auf Grund” gelaufen   Wien/Freetown/Conakry (APA) – Die Pharmaindustrie, wenig...

Sterblichkeit durch Verkehrsunfälle sinkt: Neue Studie in Lancet erschienen

Sterblichkeit durch Verkehrsunfälle sinkt in Österreich, mehr Leben werden durch chronische Nierenerkrankungen und Alzheimer verloren Die mittlere Lebenserwartung stieg in Österreich 2013 für Männer auf 78,3 Jahre und für Frauen auf 83,1 Jahre ...

Möglicher Therapieansatz bei Rippenfellkrebs gefunden

Wien (OTS) – Ein Forschungsteam der MedUni Wien konnte erstmals zeigen, dass die Hemmung eines bestimmten Wachstumsfaktors (FGF) bei Rippenfellkrebs die Aggressivität des Tumors bremst und gleichzeitig auch die Wirkung der begleitenden Chemo- ...

Nationalstiftung investiert 63 Millionen Euro in die österreichische Forschung

Wien (OTS) – Schwerpunkte liegen auf Grundlagenforschung, Standortsicherung, Stärkung des Humanpotenzials und Risikokapitals,Stärkung des Innovationspotenzials durch “Open Innovation” sowie Stärkung der Forschungsinfrastruktur un...

Gremium Gesundheitsziele: 1,5 Millionen Euro für die Stärkung der Gesundheitskompetenz

Acht Projekte erhalten entsprechend dem Förderschwerpunkt 2014 eine Finanzierungszusage Wien (OTS) – 1,5 Millionen Euro stellen die Pharmawirtschaft und Sozialversicherung für Projekte zur Verfügung, die mit konkreten Maßnahmen die Gesundhe...

Stammzellentherapie gibt erste Hoffnung für Schmetterlingskinder

Berthold unterstützt neuartige Therapieform bei Epidermolysis bullosa Salzburg (OTS) – Epidermolysis bullosa (EB) ist eine unheilbare Hauterkrankung, bei der die Patientinnen und Patienten an belasteten Stellen Blasen entwickeln. Bislang war e...

Merck acquires Swiss firm OncoEthix

Hot on the heals of its Cubist buyout Merck has confirmed the acquisition of OncoEthix, a Swiss based firm which specialises in oncology drug development. Through the takeover Merck attains investigational novel oral BET (bromodomain) inhibitor OTX015 – that is currently in Phase Ib studies for the treatment of advanced solid tumours.  read more

Roche dealt with two late-stage blows

Swiss giant Roche’s breast cancer treatment Kadcyla has failed to meet its primary endpoint and its investigational Alzheimer’s treatment trial has been stopped early, in a double blow of bad news for the firm. The results from 1,100 people found that Kadcyla (trastuzumab emtansine), either alone or in combination with Perjeta (pertuzumab), had no effect on how long people with previously untr...

Optimizing Workflow with 96- & 384-well Microplates

INTEGRA has introduced a Three Position Stage for its VIAFLO 96 and VIAFLO 384 handheld benchtop pipettes. The new accessory expands available stage positions for microplates, reservoirs and tips on a VIAFLO 96 or VIAFLO 384 from 2 to 3 thereby enhancing workflow in a wide range of applications.  Beneficially the Three Position Stage also features an indexing function to allow access to 384-w...

GSK shingles vaccine on form

GlaxoSmithKline will be celebrating following the successful Phase III study of its shingles vaccine HZ/su that has met its primary endpoint. HZ/su reduced the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo in a trial involving more than 16,000 people. read more

NHS not au fait with mobile-savvy patients

The NHS is failing to keep up with its digital generation of patients, a recent study has found.  Despite a 118% increase in mobile visits to hospital websites, only 43% of these sites have been found to be mobile-optimised. And according to digital healthcare agency Integrated Change who compiled the research, 36% of NHS website visits in August alone were from mobiles or tablets.  ...

New Lyrica formulation effective in trials

Pfizer has reported positive Phase III results for a new formulation of its painkiller Lyrica. In the study, a controlled-release formulation of Lyrica (pregabalin) showed ‘statistically significant’ positive results for the treatment of postherpetic neuralgia (pain after shingles, or PHN). read more

From Single Product to Booming Electrophoresis Portfolio

When Labnet International launched its Electrophoresis and Molecular Biology product line in 2002, it included a single Horizontal Gel Electrophoresis unit. Labnet has since expanded the product line to include more than 30 electrophoresis products, plus a host of product accessories. In the past 18 months, Labnet has doubled its Electrophoresis offering. Power supplies range from space saving uni...

Christmas Message from Bionow

As 2014 draws to a close we thought we’d take his opportunity to give a round-up of happenings throughout the course of the year as we look forward to 2015.Throughout 2014 we delivered a great program of events . . . which will all run again in...

Thursday 18th December 2014

EquipNet Expands Business in Australia and South East Asia

Strategic partnership with GraysOnline opens new opportunities in fast-growing markets Leading global asset management specialist, EquipNet Inc. (Boston, Massachusetts, USA), has announced an expansion in the Australian and South East Asia markets through a new strategic alliance with GraysOnline. The agreement combines EquipNet’s strengths as the world’s leading asset management compa...

CBSA 2014 Member Benefits Report

Thank you for your membership!  We strive to offer the highest level of service to our members and value your partnership in that effort.  Colorado continues to plays a leadership role for the bioscience industry across the nation, with the...

Humira biosimilar released in India

Indian firm Zydus Cadila has launched the first biosimilar of AbbVie’s anti-inflammatory medicine Humira, the world’s biggest-selling drug. Used as a treatment in various forms of arthritis and ankylosing spondylitis – Zydus Cadila’s copy will be branded as Exemptia in India and will cost a fifth of Humira’s (adalimumab) $1,000 per-vial US price. read more

Biochemize and Polyclone sign collaboration agreement in field of enzyme engineering

The agreement came out of Catalan participation in the European Business and Technology Center’s biotechnology mission to India

BILAT USA 2.0 to hold workshop on enhancing innovation collaboration through policy measures

The activity has come out of a previous event entitled 'Accelerating EU-US business collaboration in Health/e-health Research & Innovations'

Government plans £6 billion precision medicine strategy

The government has committed to a £6 billion investment in scientific research and development as part of its science and innovation strategy for the UK. The strategy includes plans for a new research hub in precision medicine due to open in 2015. The new centre will extend the government’s Catapult network – the elite technology and innovation centres, the Catapults, that focus on sectors or...

Lundbeck scraps stroke drug

Lundbeck has stopped development of its investigational stroke drug desmoteplase following disappointing results from its Phase III studies. The DIAS-3 trial suggested that in most patients the drug had no benefit over placebos in reducing disability symptoms associated with acute ischemic stroke (AIS). Although Lundbeck said that a few patient subgroups in both this trial and the more recent DIAS...

AstraZeneca ovarian cancer drug approved in Europe

The European Commission has approved AstraZeneca’s Lynparza for the treatment of advanced BRCA-mutated ovarian cancer. Lynparza (olaparib) has been approved for use with patients who are in complete or partial response to chemotherapy and to treat adult patients with relapsed ovarian, fallopian tube, or primary peritoneal cancers. “We are delighted to be able to bring this much needed treatmen...

Roche wins drug discovery award for Gazyvaro

Roche has been named the winner of the 2015 Drug Discover of the Year award by the British Pharmacological Society (BPS) for its leukaemia medicine Gazyvaro. Gazyvaro (obinutuzumab), marketed as Gazyva outside the EU, is the first in a new class of antibody drugs that treat chronic lymphocytic leukaemia (CLL) by attacking cells both directly and together with the immune system. read more

Search BioPortfolio: